Home » Healthcare » Pharmaceuticals » Vasculitis Treatment Market

Vasculitis Treatment Market By Drug Class (Biologics, Corticosteroids and Immunosuppressant), By Disease Condition (Large Vessel Vasculitis, Medium Vessel Vasculitis and Small Vessel Vasculitis) – Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Summary
Table Of Content

Industry Outlook

The vasculitis treatment market is expected to reach US$ 601.2 million by 2026, up from US$ 365.1 million in 2017, with a consistent compound annual growth rate (CAGR) of 5.7% from 2018 to 2026. According to the Vasculitis Foundation’s 2016 report, the global prevalence of vasculitis is 1-9 per 100,000 people. Vasculitis shows a high degree of incidence in the Caucasian population and is widely prevalent in the Scandinavian countries. Earlier, cyclophosphamide was considered the first line of treatment for all types of vasculitis. In 2010, the United States Food and Drug Administration (USFDA) approved rituximab for the treatment of vasculitis along with prednisolone. Pharmaceutical and biotechnology industries are constantly striving to achieve a targeted drug therapy approach for the treatment of vasculitis, majorly focusing on monoclonal antibodies such as tocilizumab, mepolizumab, and infliximab. CCX168, developed by ChemoCentryx and currently under phase II clinical trials, is an immunosuppressant projected to enter the market by 2021 and is anticipated to register impressive growth during the forecast period for the treatment of ANCA-associated vasculitis. In 2017, North America held the largest market share in the vasculitis treatment market on account of the developed healthcare infrastructure and increased public health awareness that resulted in early vasculitis diagnosis. North America is the domicile of key players engaged in the treatment of vasculitis disease, which contributes to its dominance in this market. Asia Pacific will register significant growth during the forecast period owing to a huge geriatric population suffering from large vessel vasculitis and a supportive regulatory environment for the treatment of vasculitis disease.

Market Synopsis

Better Clinical Outcomes in Vasculitis Treatment Will Contribute to the Biologics Segment Growth

Currently, biologics are leading the market by drug class segment and will continue to showcase excellent growth during the forecast period. In 2010, the USFDA gave approval to rituximab for the treatment of vasculitis disease in combination with prednisolone. The dosage regimen currently postulated for rituximab throughout the globe is the 4+2 protocol. Because of improved drug safety and efficacy, as well as the rising prevalence of antineutrophil cytoplasmic autoantibodies (ANCA) associated renal vasculitis in the elderly population, biologics accounted for 38.98% of the drug class segment’s share in 2017. The only limitation of using rituximab therapy is its high cost, which hinders treatment in poor nations. Cyclophosphamide is used in patients showing resistance to rituximab therapy, and its relatively low treatment cost contributes to its market growth in developing nations.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Accurate Diagnosis of Small Vessel Vasculitis is Expected to Have the Highest Double-Digit CAGR During the Forecast Period

The challenge that usually occurs during the diagnosis of vasculitis is its overlapping symptoms with those of other inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, etc. Because of the non-specificity of serological markers and irrational tissue biopsy, there is ambiguity. Leucocytes are the primary inflammatory mediators that occur at the onset of vasculitis. The factors responsible for the accurate diagnosis of vasculitis are the technological advancement in diagnostic kits and the availability of skilled workers to perform the diagnosis. In 2017, large vessel vasculitis occupied 45% of the overall vasculitis disease epidemiology. The key attributes favoring the dominance of large vessel vasculitis are the rising prevalence of immunocompromised patients and medicine-related adverse events encountered in Caucasian populations. Small vessel vasculitis will showcase impressive growth during the forecast period owing to the increasing number of blood vessel aneurysm cases encountered in the Mongolian population and the rampant growth in the reported cases of small vessel vasculitis initiated due to pesticide and chemical exposure.

Raising public health awareness in Asia-Pacific will pave the way for rapid growth during the forecast period.

In 2017, North America occupied 35.96% of the global market share for vasculitis treatment. The key factors responsible for the North American market’s growth are the rising prevalence of large vessel vasculitis, the presence of key players such as Bristol-Myers Squibb Company, Celgene Corporation, etc., and the existence of advanced healthcare facilities. Asia Pacific will be the fastest-growing market on account of a large geriatric population suffering from small vessel vasculitis, enhanced funding by pharmaceutical companies in the R&D segment, and rising public health awareness resulting in early diagnosis and treatment.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The Vasculitis Treatment Market Report provides quantitative analysis as well as the most recent market trends. The market is segmented by drug class, disease condition, and geography.

A market assessment is performed in order to understand the prevailing market trends in the vasculitis treatment market. The market estimation is done by providing the compounded annual growth rate (CAGR) and data forecast for 2018–2026. The product portfolio is helpful in giving information on the FDA-approved drugs currently prescribed for the treatment of vasculitis disease. Strategic collaboration, mergers, and acquisitions among the key players for developing an impressive product pipeline are mentioned in the business strategy section. The key players currently engaged in the vasculitis treatment market are F. Hoffmann-La Roche Ltd., AstraZeneca, Baxter International, Bristol-Myers Squibb Company, Celgene Corporation, ChemoCentryx, Daiichi Sankyo, Eli Lilly & Company, GlaxoSmithKline Plc, Merck & Co., and Novartis AG.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

How will the global vasculitis treatment market perform during the forecast period from 2018 to 2026?
What are the latest trends in the vasculitis treatment market and the most valuable opportunities for the key players?
Who is the leading player in the global vasculitis treatment market?
Which is the leading and fastest-growing region in the global vasculitis treatment market?
What are the methods of diagnosis employed for the confirmation of vasculitis disease?
Currently, what are the treatment guidelines used for the management and treatment of vasculitis disease?
What impact would the pipeline drugs have on the global vasculitis treatment market?
What are the drivers and restraints governing the global vasculitis treatment market?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global VT Market Portraiture
2.2. Global VT Market, by Drug Class, 2017 (US$ Mn)
2.3. Global VT Market, by Disease Condition, 2017 (US$ Mn)
2.4. Global VT Market Share, by Geography, 2017 (US$ Mn)

Chapter 3. Vasculitis Treatment (VT): Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global VT Market, by Key Players, 2017

Chapter 4. Global Vasculitis Treatment (VT) Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Biologics
4.2.1. Rituximab
4.2.2. Infliximab
4.2.3. Adalimumab
4.3. Corticosteroids
4.3.1. Prednisone
4.3.2. Methylprednisolone
4.4. Immunosuppressant
4.5. Pipeline Analysis
4.5.1. Tabular Representation of Phase I and Phase II Drugs

Chapter 5. Global Vasculitis Treatment (VT) Market, by Disease Condition, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Large Vessel Vasculitis
5.3. Medium Vessel Vasculitis
5.4. Small Vessel Vasculitis

Chapter 6. Global Vasculitis Treatment (VT) Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.1.1. North America VT Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.1.2. North America VT Market, by Disease Condition, 2016 – 2026 (US$ Mn)
6.1.3. North America VT Market, by Country, 2016 – 2026 (US$ Mn)
6.1.3.1. U.S.
6.1.3.2. Canada
6.2. Europe VT Market Analysis, 2016 – 2026
6.2.1. Europe VT Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.2.2. Europe VT Market, by Disease Condition, 2016 – 2026 (US$ Mn)
6.2.3. Europe VT Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific VT Market Analysis, 2016 – 2026
6.3.1. Asia Pacific VT Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.3.2. Asia Pacific VT Market, by Disease Condition, 2016 – 2026 (US$ Mn)
6.3.3. Asia Pacific VT Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America VT Market Analysis, 2016 – 2026
6.4.1. Latin America VT Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.4.2. Latin America VT Market, by Disease Condition, 2016 – 2026 (US$ Mn)
6.4.3. Latin America VT Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa VT Market, 2016 – 2026
6.5.1. Middle East & Africa VT Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.5.2. Middle East &Africa VT Market, by Disease Condition, 2016 – 2026 (US$ Mn)
6.5.3. Middle East & Africa VT Market Analysis, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa

Chapter 7. Company Profiles
7.1. F.Hoffman La Roche Ltd.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. AstraZeneca
7.3. Baxter International
7.4. Bristol Myers Squibb Company
7.5. Celgene Corporaion
7.6. ChemoCentryx
7.7. Daiichi Sankyo
7.8. Eli Lilly & Company
7.9. GlaxoSmithKline Plc
7.10. Merck & Co.

List of Figures

FIG 1. Vasculitis Treatment (VT) Market: Research Methodology
FIG 2. VT : Market Segmentation
FIG 3. Global VT Market, by Drug Class, 2017 (US$ Mn)
FIG 4. Global VT Market, by Disease Condition, 2017 (US$ Mn)
FIG 5. Global VT Market, by Geography, 2017 (US$ Mn)
FIG 6. Attractive Investment Proposition, by Geography, 2017
FIG 7. Competitive Analysis: Global VT Market, by Key Players, 2017
FIG 8. Global Rituximab Market in VT , 2016-2026(US$ Mn)
FIG 9. Global Infliximab Market in VT , 2016-2026 (US$ Mn)
FIG 10. Global Adalimumab Market in VT , 2016-2026 (US$ Mn)
FIG 11. Global Prednisone Market in VT , 2016-2026 (US$ Mn)
FIG 12. Global Methylprednisolone Market in VT , 2016-2026 (US$ Mn)
FIG 13. Global Immunosuppressant Market in VT , 2016-2026 (US$ Mn)
FIG 14. Global Large Vessel Vasculitis Market in VT , 2016-2026 (US$ Mn)
FIG 15. Global Medium Vessel Vasculitis Market in VT , 2016-2026 (US$ Mn)
FIG 16. Global Small Vessel Vasculitis Market in VT , 2016-2026 (US$ Mn)
FIG 17. U.S. VT Market, 2016-2026 (US$ Mn)
FIG 18. Canada VT Market, 2016-2026 (US$ Mn)
FIG 19. U.K. VT Market, 2016-2026 (US$ Mn)
FIG 20. Germany VT Market, 2016-2026 (US$ Mn)
FIG 21. Rest of Europe VT Market, 2016-2026 (US$ Mn)
FIG 22. China VT Market, 2016-2026 (US$ Mn)
FIG 23. Japan VT Market, 2016-2026 (US$ Mn)
FIG 24. Rest of Asia Pacific VT Market, 2016-2026 (US$ Mn)
FIG 25. Brazil VT Market, 2016-2026 (US$ Mn)
FIG 26. Mexico VT Market, 2016-2026 (US$ Mn)
FIG 27. Rest of Latin America VT Market, 2016-2026 (US$ Mn)
FIG 28. GCC VT Market, 2016-2026 (US$ Mn)
FIG 29. Rest of Middle East and Africa VT Market, 2016-2026 (US$ Mn)

List of Tables

TABLE 1 Global Vasculitis Treatment (VT) Market Portraiture
TABLE 2 Global VT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global Biologics Market in VT , 2016 – 2026 (US$ Mn)
TABLE 4 Global Corticosteroids Market in VT , 2016 – 2026 (US$ Mn)
TABLE 5 Pipeline Analysis: Phase I and Phase II Drugs
TABLE 6 Global VT Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 7 Global VT Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 8 North America VT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 North America VT Market, by Disease Condition, 2016 – 2026 (US$ Mn
TABLE 10 North America VT Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 11 Europe VT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Europe VT Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 13 Europe VT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Asia Pacific VT Market, by Drug Condition, 2016 – 2026 (US$ Mn)
TABLE 15 Asia Pacific VT Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 16 Asia Pacific VT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 Latin America VT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 18 Latin America VT Market, by Disease Condition, 2016 – 2026 (US$ Mn
TABLE 19 Latin America VT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 Middle East and Africa VT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 21 Middle East and Africa VT Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 22 Middle East and Africa VT Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 23 F.Hoffman La-Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 AstraZeneca: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Baxter International: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Bristol Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Celgene Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 ChemoCentryx: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Daiichi Sankyo: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 GlaxoSmithKline Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 Merck & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Questions:

What is the size of Vasculitis Treatment Market?

The market for Vasculitis Treatment is expected to reach US$ XX Mn in 2026.

What is the Vasculitis Treatment Market CAGR?

The Vasculitis Treatment market is expected to see significant CAGR growth over the coming years,at 5.7%.

What is the Forecast period considered for Vasculitis Treatment Market?

The report is forecasted from 2018-2026.

What is the base year considered for Vasculitis Treatment Market?

The base year of this report is 2017.

Who are the major players in this Market?

F.Hoffman La Roche Ltd., Astra Zeneca, Baxter International, Bristol Myers Squibb Company, Celgene Corporaion are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –